The purpose of this study is to test a potential new treatment for Invasive Pulmonary Aspergillosis (IPA), a fungal lung infection that mainly affects individuals with a weakened immune system.
The current approved treatment for IPA is given orally or as an IV. This study is of the same medication but administered through inhalation. This means the medication is delivered directly to where it is needed and might allow lower doses to be effective.
This inhalation method was previously tested in participants without asthma and was found to be well-tolerated. In this study we want to see how the medication is tolerated and metabolised by people with asthma, to prepare for potential future studies with people who have IPA.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!
Suitable Preventer Types